EUCTR2018-002607-34-IT进行中（未招募）1 期
Phase II, open-label study of atezolizumab in a CoHort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histologiCal subtypEs – CHANCE trial - CHANCE TRIA
GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)0 个研究点目标入组 43 人开始时间: 2021年1月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Locally advanced, relapsed or metastatic non-small cell lung cancer – stage IIIB/IV.
- •Histologically confirmed diagnosis of non-small cell lung cancer with rare histological subtype, according to World Health Organization (WHO) 2015 classification.
- •Histologic subtype variants to be enrolled into the study include: large cell neuroendocrine carcinoma (LCNEC);
- •Availability of tumor sample (material obtained from core-biopsy or surgical specimen) for central pathology revision is mandatory.
- •Availability of a formalin-fixed, paraffin-embedded tumor block or 7-10 unstained tumor slides suitable for PD-L1 expression assessment is mandatory. The assessment of PD-L1 expression will be performed by using both SP-142 and SP-263 antibody assays. The collection of tumor sample should be performed before patients are enrolled into the study .
- •Male and female and = 18 years of age.
- •Life expectancy = 12 weeks.
- •Progressive disease after or during at least one previous standard chemotherapy line.
- •Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1); clear radiological evidence of disease progression after previous treatment has to be documented.
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
- •Patients with treated brain metastases with stable lesions for at least 2 weeks either off steroids or on a stable dose or decreasing dose of steroids (= 10 mg prednisone or equivalent daily) will be enrolled. Radiotherapy must have been completed a minimum of 14 days prior to registration, and patients must have recovered from adverse events (AEs) related to radiotherapy to < grade 1 (except alopecia).
- •For Females: must be postmenopausal for at least 1 year before the screening visit, or are surgically sterile or not sexually active. Women of childbearing potential (WOCBP) must use 2 effective methods of contraception with a failure rate of less than1% per year, during the entire study treatment period and for a period of 5 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. WOCBP must have a negative serum pregnancy test during the screening period.
- •Adequate haematological function defined by white blood cell count =2,500/mm3 with absolute neutrophil count =1,500/mm3, platelet count =100,000/mm3 and haemoglobin =9g/dL.
- •Adequate hepatic function defined by a total bilirubin = 1.5 x the upper limit of normal (ULN) range (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL), serum alanine aminotransferase and aspartate aminotransferase = 2.5 x ULN.
- •Adequate renal function defined by a serum creatinine = 1.5 x ULN or an estimated creatinine clearance of = 30 mL/minute for patients with creatinine levels above institutional limits (if using the Cockcroft-Gault formula).
- •Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks before registration, and otherwise noted in other inclusion/exclusion criteria.
- •Recovered (i.e., = Grade 1 toxicity) from effects of prior anticancer therapy, except alopecia.
- •Ability to comply with protocol requirements.
- •The patient is able to provide written informed consent before performance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subject
排除标准
- •Prior treatment with Atezolizumab or any other immunotherapy agents (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways).
- •Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
- •Concurrent anticancer treatment, immune therapy, or cytokine therapy, except for erythropoietin.
- •Major surgery for any reason within 4 weeks (or 2 weeks for minor surgery) from registration and/or if the subject has not fully recovery from the surgery within 4 weeks of registration.
- •Subjects receiving immunosuppressive agents such as steroids for any reason should be tapered off these drugs before initiation of the trial treatment. Corticosteroid therapy with a dose = 10 mg prednisone or equivalent will be allowed. Note:
- •o Subjects receiving bisphosphonates or denosumab are eligible provided treatment was initiated at least 14 days before first dose of trial treatment
- •o Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be =10 mg per day of equivalent prednisone.
- •Persisting toxicity related to prior therapy of grade >1 according to National Cancer Institute - Common Terminology Criteria Adverse Event (NCI-CTCAE) v. 4.03.
- •Known severe hypersensitivity reactions to chimeric or monoclonal antibodies, fusion proteins (grade =3 NCI-CTCAE v. 4.03).
- •Patients with untreated, symptomatic and/or progressive brain metastases, or with carcinomatous meningitis.
- •History of autoimmune disease.
- •Any medical condition requiring a systemic corticosteroid treatment at doses >10 mg prednisone per day or equivalent or other immunosuppressive therapies.
- •Other concurrent neoplasms.
- •Prior organ transplantation, including allogenic stem-cell transplantation.
- •Any medical condition, within 6 months before receiving the first dose of study drug, considered relevant by Investigator. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed. Patients who present particular clinical conditions or relevant comorbidity may be enrolled into the study upon discussion with the Study Coordinator.
- •Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- •Any positive test for hepatitis C virus at screening
- •Any positive test indicating active hepatitis B infection; patients with positive total HBcAb test followed by a negative HBV-DNA test at screening could be enrolled, according to hepatologist counselling
- •Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
- •Active tuberculosis.
- •Pregnancy or breastfeeding.
- •Vaccination within 4 weeks of the first dose of atezolizumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated flue vaccines)
- •Unwilling or unable to comply with the protocol or cooperate fully with the investigator and site person
研究者
相似试验
进行中（未招募）
1 期
Atezolizumab and bevacizumab study for non small cell lung cancer patients with high-intermediate tumour mutation burdeon small cell lung cancerMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004654-17-ESFundación GECP102
进行中（未招募）
1 期
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have already received chemotherapy and radiotherapyon-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non-small cell lung cancer stage III Class: 100000004864CTIS2023-503756-27-00F. Hoffmann-La Roche AG130
进行中（未招募）
1 期
Study to assess efficacy of Atezolizumab in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastases (ATEZO-BRAIN)Atezolizumab combined with carboplatin and pemetrexedMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-005154-11-ESSpanish Lung Cancer Group (SLCG/GECP)40
进行中（未招募）
2 期
CCH1907/MK008 trialunresectable alveolar soft tissue sarcomaadvanced alveolar soft part sarcomaD018234JPRN-jRCT2031200041Yonemori Kan20
进行中（未招募）
1 期
Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in patients with a specific type of advanced breast cancer called triple negative breast cancer.CTIS2024-514031-20-00Istituto Europeo Di Oncologia S.r.l.40